TY - JOUR
T1 - Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia
AU - Acosta-Tejeda, Maribel
AU - Baptista-González, Héctor
AU - Rosenfeld-Mann, Fany
AU - Trueba-Gómez, Rocio
AU - García-Latorre, Ethel
N1 - Funding Information:
This research project received financial support from federal funds allocated to the Instituto Nacional de Perinatología, protocol number 212250-07271.
PY - 2011/10
Y1 - 2011/10
N2 - Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms.
AB - Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms.
KW - Carboxypeptidase B2 (CPB2)
KW - Carboxypeptidase U
KW - Thrombin-activated fibrinolysis inhibitor (TAFI)
KW - preeclampsia
KW - thrombophilia
UR - http://www.scopus.com/inward/record.url?scp=80054930072&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2011.05.019
DO - 10.1016/j.thromres.2011.05.019
M3 - Artículo
C2 - 21708401
SN - 0049-3848
VL - 128
SP - e39-e42
JO - Thrombosis Research
JF - Thrombosis Research
IS - 4
ER -